Monday, March 26, 2018
UPDATE 2-Roche's Tecentriq cocktail adds to lung cancer survival success
ZURICH, March 26 (Reuters) - Roche's Tecentriq immunotherapy combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss company said as it seeks an edge on Merck and Bristol-Myers Squibb.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment